Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations

Eli Lilly & Co. (LLY), AstraZeneca (AZN) Extend Immuno-Oncology Collaboration

October 22, 2015 6:21 AM EDT

Eli Lilly & Co. (NYSE: LLY) and AstraZeneca (NYSE: AZN) announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

Under the terms of the expanded agreement, Lilly and AstraZeneca will evaluate the safety and efficacy of a range of additional combinations across the companies' complementary portfolios. Lilly will lead the execution of the studies, while both companies will contribute resources. Additional... More